SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
SpringWorks Therapeutics (SWTX) has announced it will host a conference call and webcast on Thursday, February 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results along with recent business updates. The commercial-stage biopharmaceutical company, which focuses on severe rare diseases and cancer, will provide access to the live webcast with accompanying slides. Participants wishing to join the conference call need to pre-register to receive dial-in details. A replay of the webcast will be temporarily available on the company's investor relations website.
SpringWorks Therapeutics (SWTX) ha annunciato che ospiterà una teleconferenza e un webcast il giovedì 20 febbraio 2025, alle 8:30 ET per discutere i risultati finanziari del quarto trimestre e dell'anno intero 2024, insieme agli aggiornamenti recenti sull'azienda. L'azienda biofarmaceutica in fase commerciale, che si concentra su malattie rare severe e sul cancro, fornirà l'accesso al webcast dal vivo con le relative slide. I partecipanti che desiderano unirsi alla teleconferenza devono registrarsi in anticipo per ricevere i dettagli per il collegamento. Una registrazione del webcast sarà temporaneamente disponibile sul sito web delle relazioni con gli investitori dell'azienda.
SpringWorks Therapeutics (SWTX) ha anunciado que llevará a cabo una llamada de conferencia y un webcast el jueves 20 de febrero de 2025, a las 8:30 a.m. ET para discutir los resultados financieros del cuarto trimestre y del año completo 2024, así como las actualizaciones recientes del negocio. La compañía biofarmacéutica en etapa comercial, que se enfoca en enfermedades raras severas y cáncer, proporcionará acceso al webcast en vivo con las diapositivas correspondientes. Los participantes que deseen unirse a la llamada de conferencia deben registrarse previamente para recibir los detalles de marcado. Una repetición del webcast estará temporalmente disponible en el sitio web de relaciones con inversores de la empresa.
SpringWorks Therapeutics (SWTX)는 2025년 2월 20일 목요일 오전 8시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최하여 2024년 4분기 및 전체 연도 재무 결과 및 최근 비즈니스 업데이트에 대해 논의할 것이라고 발표했습니다. 중증 희귀 질환과 암에 집중하는 상업 단계의 바이오 제약 회사는 관련 슬라이드와 함께 라이브 웹캐스트에 대한 액세스를 제공할 것입니다. 컨퍼런스 콜에 참여하고자 하는 참가자는 전화 연결 정보를 받기 위해 사전 등록해야 합니다. 웹캐스트의 재생은 회사의 투자자 관계 웹사이트에서 일시적으로 제공될 것입니다.
SpringWorks Therapeutics (SWTX) a annoncé qu'il organisera une conférence téléphonique et un webinaire le jeudi 20 février 2025 à 8h30 ET pour discuter des résultats financiers du quatrième trimestre et de l'année entière 2024, ainsi que des mises à jour récentes de l'entreprise. La société biopharmaceutique en phase commerciale, qui se concentre sur les maladies rares graves et le cancer, fournira un accès au webinaire en direct avec des diapositives accompagnantes. Les participants souhaitant rejoindre la conférence téléphonique doivent s'inscrire à l'avance pour recevoir les détails de connexion. Une rediffusion du webinaire sera temporairement disponible sur le site Web des relations investisseurs de l'entreprise.
SpringWorks Therapeutics (SWTX) hat angekündigt, dass am Donnerstag, den 20. Februar 2025, um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden wird, um die Finanzzahlen des vierten Quartals und des gesamten Jahres 2024 sowie aktuelle Geschäftsinformationen zu diskutieren. Das kommerzielle Biopharmaunternehmen, das sich auf schwere seltene Krankheiten und Krebs spezialisiert hat, wird Zugang zum Live-Webcast mit entsprechenden Folien bieten. Teilnehmer, die an der Telefonkonferenz teilnehmen möchten, müssen sich im Voraus registrieren, um die Einwahldaten zu erhalten. Eine Wiederholung des Webcasts wird vorübergehend auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates.
To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contact:
Investors
investors@springworkstx.com
FAQ
When will SpringWorks Therapeutics (SWTX) report Q4 and full-year 2024 earnings?
How can investors access SWTX's Q4 2024 earnings call?
Will SWTX's Q4 2024 earnings presentation slides be available?
Where can investors find the replay of SWTX's Q4 2024 earnings call?
